AxoGen (AXGN) Stock Price, News & Analysis

Company Overview

AxoGen, Inc. (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body. AxoGen also offers the Axoguard Nerve Connector and Axoguard Nerve Protector, which are designed to support nerve repair and protect repaired nerves during healing. Its products are used by surgeons in areas including upper- and lower-extremity reconstruction, trauma care, and other peripheral nerve procedures.

AxoGen is headquartered in Alachua, Florida, and markets its products primarily through the United States, while also serving selected international markets. The company was established in the early 2000s and has built its business around specialized technologies for peripheral nerve repair. Karen Zaderej has served as AxoGen’s chief executive officer and has been associated with the company’s development as a commercial medical-device business.

Key Stats

• Today's Range: $48.08 to $49.88
• 50-Day Range: $34.62 to $51.73
• 52-Week Range: $21.68 to $52.91
• Volume: 1.83 million shs
• Average Volume: 1.98 million shs
• Market Capitalization: $2.95 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.92
• Consensus Rating: Moderate Buy

AxoGen Stock Analysis - MarketRank™

AxoGen scored higher than 66% of companies evaluated by MarketBeat, and ranked 380th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AxoGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

AxoGen has a consensus price target of $57.92, representing about 17.3% upside from its current price of $49.37.

Amount of Analyst Coverage

AxoGen has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AxoGen are expected to grow in the coming year, from ($0.44) to $0.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AxoGen is -75.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AxoGen is -75.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AxoGen has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.77% of the float of AxoGen has been sold short.

Short Interest Ratio / Days to Cover

AxoGen has a short interest ratio ("days to cover") of 3.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AxoGen has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AxoGen does not currently pay a dividend.

Dividend Growth

AxoGen does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.77

News Sentiment

AxoGen has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 34 news articles for AxoGen this week, compared to 4 articles on an average week.

Search Interest

8 people have searched for AXGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,656,947.00 in company stock.

Percentage Held by Insiders

2.44% of the stock of AxoGen is held by insiders.

Percentage Held by Institutions

80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/28/2026
• Today: 10/31/2026
• Investor update: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:AXGN
• CIK: 805928
• Web: www.axogeninc.com
• Phone: (386) 462-6800
• Fax: 386-462-6801
• Employees: 622
• Year Founded: 2002

Price Target and Rating

• Average Price Target for AxoGen: $57.92
• High Price Target: $65.00
• Low Price Target: $52.00
• Potential Upside/Downside: +17.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.70 million
• Net Margins: -11.96%
• Pretax Margin: -11.96%
• Return on Equity: -5.35%
• Return on Assets: -4.41%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 12.02
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: $225.21 million
• Price / Sales: 13.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.31 per share
• Price / Book: 5.94

Miscellaneous

• Outstanding Shares: 59,730,000
• Free Float: 52,450,000
• Market Cap: $2.95 billion
• Optionable: Optionable
• Beta: 1.17